Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox)
Author(s): Ip Kendice, Carvalho Maria, Shan Ashley, Banov Daniel
Issue: Jul/Aug 2017 - Volume 21, Number 4
View All Articles in Issue
Page(s): 322-329
Download in electronic PDF format for $75
Abstract: Budesonide is a corticosteroid that has been shown effective in the treatment of eosinophilic esophagitis, but there are currently no commercial medicines to treat this chronic allergic/immune condition, despite its prevalence in the U.S. Therefore, pharmaceutical compounding is the alternative choice to meet the therapeutic need of eosinophilic esophagitis patients. Two budesonide mucoadhesive oral suspensions (1 mg/10 mL and 2 mg/10 mL) were developed using the compounding vehicle MucoLox, a proprietary mucoadhesive polymer blend that promotes mucosal adhesion. The physical and chemical stability of the oral suspensions was tested over a period of 182 days, at room temperature and refrigerated conditions, in order to determine the corresponding beyond-use date. The physical characterization consisted in observing all samples for color/appearance and odor, and testing for pH and density, whereas the chemical characterization consisted in ultra-performance liquid chromatography assay testing. Both oral suspensions were proven physically and chemically stable, and the ultra-performance liquid chromatography method was proven stability indicating. As a result, the beyond-use date of the budesonide 1-mg/10-mL and 2-mg/10-mL mucoadhesive oral suspensions (MucoLox), in amber plastic bottles, is six months at both room temperature and refrigerated conditions.
Related Keywords:
budesonide, corticosteroid, asthma, inflammatory bowel disease, eosinophilic esophagitis, mucoadhesive oral suspensions, mucosal adhesion, anti-inflammatory agent, formulation, physical stability, chemical stability, forced degradation studies, stability-indicating assay, storage
Related Categories:
EXCIPIENTS, FORMULATIONS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, ALLERGY/IMMUNOLOGY/INFLAMMATION, STORAGE
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox)
Ip Kendice, Carvalho Maria, Shan Ashley, Banov Daniel
|
Jul/Aug 2017
Pg. 322-329
|
Eosinophilic Esophagitis: Treatment with Oral Viscous Budesonide
Zur Eyal
|
Jul/Aug 2012
Pg. 288-293
|
Budesonide 1-mg//10-mL Mucolox Oral Suspensions
Allen Loyd V Jr
|
Jul/Aug 2018
Pg. 317
|
Budesonide 0.0.25% Mucoadhesive Gel
Allen Loyd V Jr
|
Jul/Aug 2021
Pg. 323
|
Pluronic Lecithin Organogel for Local Delivery of Anti-Inflammatory Drugs
Frankum James, Ramsay Dale, Das Nandita G, Das Sudip K
|
Mar/Apr 2004
Pg. 101-105
|
Wetting and/or Solubilizing Agents, Featured Excipient:
Allen Loyd V Jr
|
Jul/Aug 2001
Pg. 310-312
|
Physiochemical Compatibility of Nebulizable Drug Admixtures Containing Budesonide and Colistmethate or Hypertonic Saline
Klemmer Anja, Krämer Irene, Kamin Wolfgang
|
May/Jun 2013
Pg. 254-261
|
Utilization of Compounded Medications in an Oral Medicine Practice
Stock Shannon, Rubino Katie, Woo Sook-Bon, Margolis Arthur, Thomas Irena, Aboalela Ali, Treister Nathaniel
|
Mar/Apr 2016
Pg. 155-158
|
Stability of an Alcohol-free, Dye-free Hydrocortisone (2 mg/mL) Compounded Oral Suspension
Manchanda Arushi, Laracy Melissa, Savji Taslim, Bogner Robin H
|
Jan/Feb 2018
Pg. 66-75
|
Physicochemical Stability of the Extemporaneous Ibuprofen Oral Suspension in "Wagner" Base
Spennacchio Antonio, Lopedota Angela, la Forgia Flavia, Fontana Sergio, Franco Massimo, Denora Nunzio
|
Jan/Feb 2023
Pg. 72-77
|
Quality Control and Physical and Chemical Stability of Hydrocortisone Oral Suspension: An Interlaboratory Study
Santoveña A, Llabrés M, Fariña JB
|
Sep/Oct 2010
Pg. 430-435
|
Enhancement of Skin Penetration of Nonsteroidal Anti-Inflammatory Drugs from Extemporaneously Compounded Topical-Gel Formulations
Goodwin Donald A, Fuhram L Clifton
|
Nov/Dec 1999
Pg. 496-500
|
Physicochemical and Microbiological Stability of Extemporaneously Compounded Hydrocortisone Oral Suspensions in PCCA Base, SuspendIt
Pramar Yashoda V, Mandal Tarun K, Bostanian Levon A, Kader Cyndy, Morris Tommy C, Graves Richard A
|
Sep/Oct 2021
Pg. 431-439
|
Curcumin 1% Intranasal Mucoadhesive Gel
Allen Loyd V Jr
|
Nov/Dec 2023
Pg. 490
|
Effects of Compounded Stanford Modified Oral Rinse (MucoLox) on the Survival and Migration of Oral Keratinocytes and Fibroblasts: Implications for Wound Healing
Song Guiyun, Banov Daniel, Bassani August S
|
Jan/Feb 2018
Pg. 60-65
|
Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4
Espana B, Joseph-Tornabène F, Jaquet Cécile, Perrot S, Prouillac C
|
Jul/Aug 2020
Pg. 327-336
|
Dexamethasone 1-mg/mL in Oral Mix or Oral Mix SF Suspension
Allen Loyd V Jr
|
Sep/Oct 2021
Pg. 416
|
Stability of Atenolol, Clonazepam, Dexamethasone, Diclofenac Sodium, Diltiazem, Enalapril Maleate, Ketoprofen, Lamotrigine, Penicillamine-D, and Thiamine in SyrSpend SF PH4 Oral Suspensions
Polonini HC, Loures S, Lima LC, Ferreira AO, Brandão MA
|
Mar/Apr 2016
Pg. 167-174
|
Investigation of the Physical, Chemical, and Microbiological Stability of Oral Solutions Compounded with Herbals
Khokhlova Kateryna O, Zdoryk Oleksandr A
|
May/Jun 2018
Pg. 240-246
|
Stability of Extemporaneously Prepared Hydroxycarbamide Oral Suspensions
Kabiche Djamila, Balde Issa-Bella, Majoul Elyes, Kabiche Sofiane, Bourguignon Elodie, Fontan Jean-Eudes, Cisternino Salvatore, Schlatter Joel
|
Mar/Apr 2017
Pg. 160-163
|
Return to Top |